ad

3 Heart Care Medicines Brand, Bank Technology Provider and Namkeen Snacks Maker Stocks With a Strong Future Roadmap: Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International

Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International: ROE of 15.9% to 33.7% and FY22 to FY26 revenue CAGR of 10.4% to 22.9%. Prices as of 18 Nov 2026.


19 Nov 2026 • 4:06 pm

3 Heart Care Medicines Brand, Bank Technology Provider and Namkeen Snacks Maker Stocks With a Strong Future Roadmap: Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International

Quick Answer

The three cardiac drug, bank software and namkeen stocks to watch are Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Their return on equity ranges from 15.9% to 33.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.4% to 22.9%. Oracle Financial Services Software has the highest return on equity at 33.7%, while Eris Lifesciences has the fastest revenue growth at 22.9% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.

Cardiac drug, bank software and namkeen stocks offer a focused view of a sector where demand keeps widening. Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International cover a branded medicines company, a banking software company and an ethnic snacks maker.

This list covers three cardiac drug, bank software and namkeen stocks with complete current figures: Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Cardiac Drug, Bank Software and Namkeen Stocks?

Cardiac drug, bank software and namkeen stocks are listed companies that sell branded medicines for heart and diabetes care, build software that banks use for daily operations, and make bhujia, namkeen and sweets sold across India. Their earnings depend on medicine demand, bank technology budgets and snack demand.

Cardiac Drug, Bank Software and Namkeen Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Eris Lifesciences 1,337.1 15,618 23.5 36.0 15.9 0.60
Oracle Financial Services Software 9,694.5 86,056 25.2 17.9 33.7 0.00
Bikaji Foods International 480.75 11,686 45.8 33.9 16.1 0.19

On valuation, Eris Lifesciences trades at a P/E below the industry P/E, while Oracle Financial Services Software and Bikaji Foods International trade above it, which reflects the growth the market already expects. Readers comparing cardiac drug, bank software and namkeen stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cardiac drug, bank software and namkeen stocks can use the coming numbers to test whether growth is holding.

Why Do Cardiac Drug, Bank Software and Namkeen Stocks Have a Strong Roadmap in India?

Cardiac drug, bank software and namkeen stocks have a strong roadmap in India because steady demand for chronic care medicines, banks upgrading their systems and rising demand for packaged snacks keep widening the market for these companies.

  • Branded medicines. Patients stay on long-term treatment.
  • Banking software. Banks upgrade their core systems.
  • Snacks. Households buy packaged namkeen.

Why Eris Lifesciences Features Among These Cardiac Drug, Bank Software and Namkeen Stocks

Among the cardiac drug, bank software and namkeen stocks on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Oracle Financial Services Software Features Among These Cardiac Drug, Bank Software and Namkeen Stocks

Among the chronic care medicines, bank technology and snacks shares on this list, Oracle Financial Services Software develops banking software products such as core banking, lending and risk platforms and also provides related services and support to banks and financial institutions around the world.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%.

The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P/E of 25.2, above the industry P/E of 17.9.

Roadmap: The company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.

What to watch: Follow product licence wins, cloud adoption by banking clients and the pace of new deals.

Why Bikaji Foods International Features Among These Cardiac Drug, Bank Software and Namkeen Stocks

Among the three companies on this list, Bikaji Foods International, headquartered in Bikaner, makes traditional Indian snacks such as bhujia and namkeen, along with sweets, papad and other packaged foods.

In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%.

Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 45.8, above the industry P/E of 33.9.

Roadmap: The company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.

What to watch: Track distribution expansion and input costs for edible oils and potatoes.

Eris Lifesciences vs Oracle Financial Services Software vs Bikaji Foods International on Key Financials

The table below sets the three cardiac drug, bank software and namkeen stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Eris Lifesciences 1,373 3,137 22.9% 648 20.6%
Oracle Financial Services Software 5,356 7,943 10.4% 2,639 33.2%
Bikaji Foods International 1,621 3,045 17.1% 254 8.4%

Oracle Financial Services Software posts the highest return on equity in this group at 33.7%. Oracle Financial Services Software has the largest FY26 revenue at Rs 7,943 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with cardiac drug, bank software and namkeen stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Cardiac Drug, Bank Software and Namkeen Stocks

Every theme carries risks that deserve a check before any decision. For these cardiac drug, bank software and namkeen stocks, the main points are: Long-term chronic care medicines, bank technology and snacks shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Client spending. Technology budgets can vary with global conditions.
  • Raw material costs. Ingredient and packaging prices can move margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter cardiac drug, bank software and namkeen stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Cardiac Drug, Bank Software and Namkeen Stocks

Cardiac drug, bank software and namkeen stocks reward patient research into demand, execution and financial strength. Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International each have a clear plan to grow. Based on the 18 November 2026 close, Eris Lifesciences trades at Rs 1,337.1, Oracle Financial Services Software at Rs 9,694.5 and Bikaji Foods International at Rs 480.75. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these cardiac drug, bank software and namkeen stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track cardiac drug, bank software and namkeen stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are cardiac drug, bank software and namkeen stocks?

Ans. Cardiac drug, bank software and namkeen stocks are listed companies that sell branded medicines for heart and diabetes care, build software that banks use for daily operations, and make bhujia, namkeen and sweets sold across India. Their earnings depend on medicine demand, bank technology budgets and snack demand. This list looks at three of them, Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.

Which cardiac drug, bank software and namkeen stocks are covered in this list?

Ans. This list covers Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Based on the 18 November 2026 close, Eris Lifesciences traded at Rs 1,337.1, Oracle Financial Services Software at Rs 9,694.5 and Bikaji Foods International at Rs 480.75. Their return on equity ranges from 15.9% to 33.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.4% to 22.9%.

Why do cardiac drug, bank software and namkeen stocks have a strong future roadmap in India?

Ans. Cardiac drug, bank software and namkeen stocks have a strong roadmap in India because steady demand for chronic care medicines, banks upgrading their systems and rising demand for packaged snacks keep widening the market for these companies. The main drivers are as follows. Branded medicines. Patients stay on long-term treatment. Banking software. Banks upgrade their core systems. Snacks. Households buy packaged namkeen. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Oracle Financial Services Software performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%. The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P/E of 25.2, above the industry P/E of 17.9. Looking ahead, the company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.

How has Bikaji Foods International performed financially?

Ans. Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%. Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%. In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 45.8, above the industry P/E of 33.9. Looking ahead, the company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.

What risks should investors check before buying cardiac drug, bank software and namkeen stocks?

Ans. Investors should check a few risks before buying cardiac drug, bank software and namkeen stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of cardiac drug, bank software and namkeen stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down